Combined inhibitors of angiogenesis and histone deacetylase: Efficacy in rat hepatoma

World Journal of Gastroenterology

Volumn 17, Issue 31, 2011, Pages 3623-3629

  Ganslmayer, Marion ^a   Zimmermann, Annette ^b   Zopf, Steffen ^a   Herold, Christoph ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Hepatocellular carcinoma; Histone deacetylase inhibitor; MS 275; PTK787; ZK222584

Indexed keywords

CYCLINE; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; RETINOIC ACID; TAMOXIFEN; VASCULOTROPIN RECEPTOR; VATALANIB;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; HEPATOMA CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METASTASIS; NICK END LABELING; NONHUMAN; RAT; RECOMMENDED DRUG DOSE; TREATMENT OUTCOME; TUMOR CELL; TUMOR VOLUME;

EID: 80053055560     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i31.3623     Document Type: Article

References (26)

1. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007; 37 Suppl 2: S88-S94
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576
3. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009; 15: 3210-3216
4. Ganslmayer M, Ocker M, Zopf S, Leitner S, Hahn EG, Schuppan D, Herold C. A quadruple therapy synergistically blocks proliferation and promotes apoptosis of hepatoma cells. Oncol Rep 2004; 11: 943-950
5. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327
6. Ganslmayer M, Ocker M, Kraemer G, Zopf S, Hahn EG, Schuppan D, Herold C. The combination of tamoxifen and 9cis retinoic acid exerts overadditive anti-tumoral efficacy in rat hepatocellular carcinoma. J Hepatol 2004; 40: 952-956
7. Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14: 70-76
8. Richly H, Schultheis B, Adamietz IA, Kupsch P, Grubert M, Hilger RA, Ludwig M, Brendel E, Christensen O, Strumberg D. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer 2009; 45: 579-587
9. Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-620
10. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-18
11. Thomas AL, Trarbach T, Bartel C, Laurent D, Henry A, Poethig M, Wang J, Masson E, Steward W, Vanhoefer U, Wiedenmann B. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. Ann Oncol 2007; 18: 782-788
12. Ellis LM, Rosen L, Gordon MS. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies. Clin Adv Hematol Oncol 2006; 4: suppl 1-10; quz 11-12
13. Fang JY. Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers. J Gastroenterol Hepatol 2005; 20: 988-994
14. Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG, Schuppan D. The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 2002; 36: 233-240
15. Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey MA, Horneffer YR, Juwara L, Melillo G, Ivy SP, Merino M, Neckers L, Steeg PS, Conley BA, Giaccone G, Doroshow JH, Murgo AJ. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 2010; 46: 340-347
16. Qu W, Kang YD, Zhou MS, Fu LL, Hua ZH, Wang LM. Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells. Urol Oncol 2009; 28: 648-654
17. Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 2005; 65: 3691-3699
18. Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF. Special Report: The 1996 Guide for the Care and Use of Laboratory Animals. ILAR J 1997; 38: 41-48
19. Wong CM, Ng IO. Molecular pathogenesis of hepatocellular carcinoma. Liver Int 2008; 28: 160-174
20. Matsuda Y. Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1734-1740
21. Ocker M, Alajati A, Ganslmayer M, Zopf S, Lüders M, Neureiter D, Hahn EG, Schuppan D, Herold C. The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol 2005; 131: 385-394
22. Yao DF, Wu XH, Zhu Y, Shi GS, Dong ZZ, Yao DB, Wu W, Qiu LW, Meng XY. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2005; 4: 220-226
23. Hauschild A, Trefzer U, Garbe C, Kaehler KC, Ugurel S, Kiecker F, Eigentler T, Krissel H, Schott A, Schadendorf D. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res 2008; 18: 274-278
24. Wang XF, Qian DZ, Ren M, Kato Y, Wei Y, Zhang L, Fansler Z, Clark D, Nakanishi O, Pili R. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 2005; 11: 3535-3542
25. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999; 340: 1046-1047
26. Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol 2011; 2011: 875-824